Home » Newsletters » BioWorld Science

BioWorld Science

May 2, 2003

View Archived Issues

New data on the effects of intracavernosal administration of PDE5 inhibitors

Zoledronic acid reduces skeletal morbidity associated with prostate cancer

Improved quality of life with intermittent androgen deprivation after radical prostatectomy

Praecis achieves goals in first quarter of 2003

Pravastatin reduces disease activity in mice with dextran sulfate-induced colitis

Entry inhibitors and efficacy in preventing HIV transmission

New RXR agonists and their use in diabetes and obesity disclosed by GSK

Further research on tyrosine kinase inhibitors reported by Allergan

Novel antibacterial oxazolidinones developed by Merck and Kyorin

Novel agents for enhancing DNA-damaging activity

BMS researchers identify new anti-HCV NS5B inhibitors

New antitumor camptothecins identified by Indian researchers

French team prepares and tests new agents with hypoglycemic and lipid lowering activity

Novel muscarinic M1 agonists and their use in cognition disorders described by Lilly

Merck claims androgen receptor modulators for use in bone disorders

Prous Science announces the publication of state-of-the-art review: dermatomyositis

Ranbaxy updates clinical progress in first quarter

Johnson & Johnson completes merger with Scios

Additional data and analyses submitted to FDA in support of Risperdal Consta

Patent broadens coverage of Avant's CETP vaccine technology

Additional analysis of TP-10 phase II data reveals benefit in males

MRI plus Combidex aids in assessing residual and primary brain, head and neck tumors

Early termination of FTC review for Axert rights

Pilot study for PTI-901 in IBS completes enrollment

Approval for new Zosyn dosing regimen

CPMP adopts negative opinion for Serostim for AIDS-related wasting syndrome

Travatan indication extended for first-line therapy for ocular hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 1, 2026.
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026